Ultrasensitive Detection of CNVs
NuProbe has developed an NGS panel using QASeq technology for the simultaneous and ultrasensitive detection of CNVs, indels, and SNVs in breast cancer. The panel has been tested on reference standards and clinical fresh frozen tissue, PMBCs, FFPE tissue, and cfDNA. Similar assays can be customized to target your biomarker needs. For information on available technology solutions, contact us.
QASeq Assays Portfolio
Breast Cancer +HER2 CNV NGS Panel
Accurately detect SNVs and indels in 14 genes associated with breast cancer and CNVs down to 5% ploidy in HER2.
The Breast Cancer +HER2 CNV NGS Panel detects gene mutations across 84 breast cancer hotspots in 14 genes and CNVs in HER2. Using QASeq technology, the Breast Cancer +HER2 CNV NGS Panel accurately quantifies SNVs and indels down to 0.1% VAF and CNVs in HER2 at 2.05/1.95 single heterozygous copy gain/loss from cfDNA or tumor tissue.
AKT1, AR, BRAF, BRCA1, BRCA2, EGFR, ERBB2 (HER2), ERBB3, ERBB4, ESR1, KRAS, PIK3CA, PTEN, TP53
- Detect SNVs and indels at 0.1% VAF
- Detect CNVs at 2.05/1.95 ploidy
- Compatible with tumor-derived or cell-free DNA